MARCKS and Alzheimer disease: MARCKS and GSK‐3β are both linked to CDC42 (Brudvig et al. 2018; Zhu et al. 2023), a key regulator of postsynaptic f‐actin plasticity that appears upregulated in AD patients (Zhu et al. 2023).